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Abstract
Background: There is a significant demand for colorectal cancer (CRC) screening methods that are noninvasive,
inexpensive, and capable of accurately detecting early stage tumors. It has been shown that models based on the
gut microbiota can complement the fecal occult blood test and fecal immunochemical test (FIT). However, a barrier
to microbiota-based screening is the need to collect and store a patient’s stool sample.
Results: Using stool samples collected from 404 patients, we tested whether the residual buffer containing
resuspended feces in FIT cartridges could be used in place of intact stool samples. We found that the bacterial DNA
isolated from FIT cartridges largely recapitulated the community structure and membership of patients’ stool
microbiota and that the abundance of bacteria associated with CRC were conserved. We also found that models
for detecting CRC that were generated using bacterial abundances from FIT cartridges were equally predictive as
models generated using bacterial abundances from stool.
Conclusions: These findings demonstrate the potential for using residual buffer from FIT cartridges in place of stool
for microbiota-based screening for CRC. This may reduce the need to collect and process separate stool samples
and may facilitate combining FIT and microbiota-based biomarkers into a single test. Additionally, FIT cartridges
could constitute a novel data source for studying the role of the microbiome in cancer and other diseases.
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Background
Although colorectal cancer (CRC) mortality has declined
in recent decades, it remains the second leading cause of
death among cancers in the USA [1]. Early detection of
CRC is critical since patients whose tumors are detected
at an early stage have a greater than 90 % chance of sur-
vival [1]. However, more than a third of Americans for
whom screening is recommended do not adhere to
screening guidelines [2]. The high cost and invasive na-
ture of procedures, such as colonoscopy and sigmoidos-
copy, are barriers for many people [3, 4]. Some do not
consider these invasive tests as a primary screening op-
tion, but they are in the USA [5]. Unfortunately, nonin-
vasive tests, such as the guaiac fecal occult blood test
(gFOBT), fecal immunochemical test (FIT), and the
multitarget DNA test, fail to reliably detect adenomas [6,
7] (e.g., sensitivity for nonadvanced adenomas is 7.6 % for
FIT and 17.2 % for the DNA test). Thus, there is a need
for novel noninvasive screening methods with improved
sensitivity for early stage colonic lesions.
Several studies have demonstrated the potential for
the gut microbiota to be used to detect CRC [8–11].
Moreover, we and others have shown that combining
microbiota analysis with conventional diagnostics, like
gFOBT and FIT, can significantly improve the detection
of colonic lesions over either method by itself [8, 9, 11].
One limitation of microbiota-based CRC screening is
the need to collect and process separate stool samples
for microbiota characterization. Given the widespread
use of FIT to collect specimens for screening, the ability
to use the same sample for microbiota characterization
could make processing more efficient and less expensive.
We hypothesized that the small amount of fecal material
contained in FIT sampling cartridges was sufficient to
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perform both hemoglobin quantification and microbiota
characterization. To test this hypothesis, we isolated bac-
terial DNA from the residual buffer of OC-Auto® FIT
cartridges (Polymedco Inc.) that had already been used
for quantifying fecal hemoglobin concentrations. We
then compared the bacterial composition of the FIT cart-
ridge to that of DNA isolated directly from a patient’s
stool sample and assessed the ability of FIT cartridge-
derived DNA to be used for microbiota-based CRC
screening.
Methods
Study design/diagnoses/stool collection
Stool samples were obtained through the Great Lakes-
New England Early Detection Research Network. The
study was a multicenter, prospective, cross-sectional co-
hort validation study planned for 600 participants. The
planned sample size was 200 participants with colorectal
cancer, 200 participants with colorectal adenomas, and
200 participants with normal colonoscopies. The base-
line visit was done either prior to a scheduled colonos-
copy or after a colonoscopy was done. If a subject was
suspected of having a colon adenocarcinoma or an aden-
oma, the baseline samples were collected before the col-
onoscopy or exposure to colonic preps so the lesions are
present when stool collection is done. Normal controls
were recruited at the time of their scheduled colonos-
copy, prior to their colonoscopy, or within 4 months
after completing a screening colonoscopy indicating no
adenomas or colorectal cancer to provide a set of sam-
ples. The normal patients’ stool samples were collected
before colonic preps or at least 4 weeks after the colon-
oscopy was completed. Patients were asymptomatic, at
least 18 years old, willing to sign informed consent, able
to tolerate removal of 58 mL of blood, and willing to
collect a stool sample. Patient age at the time of enroll-
ment ranged from 29 to 89 with a median of 60 years.
Patients were excluded if they had undergone surgery,
radiation, or chemotherapy for current CRC prior to
baseline samples or had inflammatory bowel disease,
known hereditary nonpolyposis CRC, or familial aden-
omatous polyposis. Patient diagnoses were determined
by colonoscopic examination and histopathological re-
view of any biopsies taken. Colonoscopies were per-
formed, and fecal samples were collected in four
locations: Toronto (Ontario, Canada), Boston (MA,
USA), Houston (TX, USA), and Ann Arbor (MI, USA).
All participants collected a whole evacuated stool in a
collection container with no preservatives. Stool samples
were collected, packed in ice, shipped to a processing
center via next day delivery, and stored at −80 °C. Fecal
material for FIT was collected from frozen stool aliquots
using OC-Auto® FIT sampling bottles (Polymedco Inc.).
FIT cartridges were stored at 4 °C for up to 48 hours
prior to hemoglobin quantification using an OC-Auto
Micro 80 automated system (Polymedco Inc.). FIT car-
tridges were then stored at −20 °C until being thawed
for DNA extraction. The University of Michigan Institu-
tional Review Board approved this study, and all subjects
provided informed consent.
16S rRNA gene sequencing
Processed FIT samples were thawed, and 100 μl of buffer
were withdrawn by pipette for DNA extraction. DNA
was isolated from the FIT cartridge buffers and the
matching stool samples from which they were collected
using the PowerSoil-htp 96 Well Soil DNA isolation kit
(MO BIO Laboratories) and an epMotion 5075 auto-
mated pipetting system (Eppendorf ). The V4 region of
the bacterial 16S ribosomal RNA (rRNA) gene was amp-
lified using custom barcoded primers and sequenced as
described previously using an Illumina MiSeq sequencer
[12]. The 16S rRNA gene sequences were curated using
the mothur software package, as described previously
[12, 13]. Curated sequences were clustered into oper-
ational taxonomic units (OTUs) using a 97 % similarity
cutoff with the average neighbor clustering algorithm.
Sequences were classified using a naive Bayesian classi-
fier trained against a 16S rRNA gene training set pro-
vided by the Ribosomal Database Project (RDP) [14].
Species-level classifications for OTUs of interest were
determined by using blastn to compare the predominant
sequence within each OTU to the NCBI 16S rRNA data-
base. The putative species was only reported for OTUs
with greater than 99 % sequence identity to a single spe-
cies in the database; otherwise, the consensus RDP clas-
sification was used.
Statistical methods
All statistical analyses were performed using R (v.3.2.0).
Random forest models were generated using the area
under the curve (AUC)-RF algorithm for feature reduc-
tion and maximizing model performance [15]. The most
predictive OTUs were determined based on mean de-
crease in accuracy when removed from the model. The
AUC of receiver operator characteristic (ROC) curves
were compared using the method described by DeLong
et al. [16] as implemented in the pROC R package [17].
There was sufficient power (80 %) to detect a 0.081 dif-
ference in AUC with alpha set at 0.05.
Results
DNA was isolated, and 16S rRNA gene sequencing was
performed on stool aliquots and the residual buffer of
paired OC-Auto® FIT sampling cartridges from 404 pa-
tients. Among these patients, 101 had CRC, 162 had ad-
enomas, and 141 had no colonic lesions. First, we tested
whether the bacterial community profiles from FIT
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cartridges recapitulated their stool counterparts. Second,
we compared the number of OTUs shared within FIT/
stool pairs from the same patient to the number of
OTUs shared between patients (Fig. 1a). FIT cartridges
and stool from the same patient (red line) had signifi-
cantly more bacterial populations in common than those
taken from different patients (p < 0.001, two-sample
Kolmogorov-Smirnov test), indicating that community
membership was conserved within patients across stool
and FIT cartridges. Third, we calculated the similarity in
community structure between samples using 1-thetaYC
index [18]. This metric compares the presence or ab-
sence of bacterial populations and their relative abun-
dance. The bacterial community structure of stool and
FIT samples from the same patient (red line) were sig-
nificantly more similar to each other than to stool or
FIT from other patients (Fig. 1b, p < 0.001). Finally, we
used a Mantel test to determine whether the patient-to-
patient thetaYC distances among stool samples were cor-
related with the patient-to-patient thetaYC distances
among FIT cartridges. We found that there was a signifi-
cant correlation (Mantel test r = 0.525, p < 0.001), sug-
gesting that the inter-patient variation in community
structure between the stool samples of patients was con-
served in samples from FIT cartridges.
Next, we observed a significant correlation between
the abundance of each genus in the paired FIT cartridge
and stool samples (Fig. 2a, Spearman’s rho 0.699, p <
0.001). This suggested that the abundance of bacterial
genera was conserved. This correlation was especially
strong when comparing the 100 most abundant genera
from stool (Spearman’s rho 0.886, p < 0.001). Several
bacterial species have been repeatedly associated with
CRC, including Fusobacterium nucleatum, Porphyromo-
nas asaccharolytica, Peptostreptococcus stomatis, and
Parvimonas micra [9–11, 19]. As expected, the abun-
dance of these species in stool was significantly corre-
lated with their abundance in matched FIT cartridges
(all p < 0.001, Spearman’s rho ≥0.352) (Fig. 2b). We ob-
served some biases in the abundance of certain taxa. In
particular, the genus Pantoea was detected in 399 of the
404 FIT cartridges with an average abundance of 2.4 %
but was only detected in 1 stool sample. The genus Heli-
cobacter was detected in 172 FIT cartridges but only 10
stool samples. Likewise, several genera of Actinobacteria
were more abundant in stool samples compared to FIT.
Notwithstanding these few exceptions, the abundance of
the vast majority of genera were well conserved between
stool and FIT cartridges. Overall, these findings sug-
gested that the overall bacterial community structure
and the abundance of specific taxa in FIT cartridges and
stool were similar.
We tested whether the bacterial relative abundances
we observed from FIT cartridges could be used to differ-
entiate healthy patients from those with carcinomas
using random forest models as we did previously using
intact stool samples [11]. Using DNA from the FIT cart-
ridge, the optimal model utilized 28 OTUs and had an
AUC of 0.831 (Fig. 3a). There was not a significant dif-
ference in the AUC for this model, and the model based
on DNA isolated directly from stool, which used 32
OTUs and had an AUC of 0.853 (p = 0.41). Furthermore,
the probabilities of individuals having lesions were corre-
lated between the models generated using DNA isolated
from the FIT cartridges and stool samples (Spearman’s
rho 0.633, p < 0.001, Fig. 3b). We also generated random
forest models for differentiating healthy patients from
those with any type of lesions (i.e., adenoma or carcin-
oma). There was not a significant difference in AUC be-
tween the stool-based model with 41 OTUs (AUC =
0.700) and the FIT cartridge-based model with 41 OTUs
(AUC = 0.686, p = 0.65, Fig. 3c). Again, the probabilities
of individuals having lesions according to the two
models were significantly correlated (Spearman’s rho
0.389, p < 0.001 Fig. 3d). These findings demonstrated
that models based on bacterial DNA from FIT cartridges
Fig. 1 Bacterial community structure from FIT cartridge recapitulates stool. Density plots showing distribution of the number of shared OTUs
(a) and community similarity (b) between groups of samples (*p < 0.001 two-sample Kolmogorov-Smirnov test)
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Fig. 2 Bacterial populations conserved between stool and FIT cartridge. a Scatter plot of the average relative abundance of each bacterial genus
in stool and FIT cartridges colored by phylum. b Scatter plots of the relative abundances of the four species frequently associated with CRC. All
correlations were greater than 0.35 (all p < 0.001)
Fig. 3 Microbiota-based models from FIT cartridge DNA are as predictive as models from stool. a ROC curves for distinguishing healthy patients
from those with cancer using microbiota-based random forest models using DNA from FIT cartridges or stool. b Probability of having cancer for
each patient according to microbiota-based models from a. c ROC curves for distinguishing patients with adenomas or carcinomas from healthy
patients using microbiota-based random forest models using DNA from FIT cartridges or stool. d Probability of having a lesion for each patient
based on the models from c
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were as predictive as models based on DNA isolated dir-
ectly from stool.
Discussion
Bacterial DNA isolated from the residual buffer of FIT car-
tridges recapitulated the community structure and mem-
bership of patients’ stool microbiota. FIT/stool pairs
collected from the same patient were significantly more
similar to each other than samples from different patients,
and the inter-patient differences in stool microbiota struc-
ture were conserved in FIT cartridge-derived microbiota.
More importantly, random forest models generated using
bacterial abundances from FIT cartridge-derived and
stool-derived DNA were equally predictive for differentiat-
ing healthy patients from those with adenomas and
carcinomas.
Sinha et al. compared a variety of sampling and stor-
age methods for fecal samples to be used for micro-
biome analyses [20]. They found reproducible biases
according to sampling method and time at ambient
temperature. Likewise, we observed biases in the abun-
dance of certain bacterial populations in FIT cartridges
compared stool. For example, an OTU associated with
Pantoea was found in 98.8 % of FIT cartridge samples
and only 0.2 % of stool samples. It is likely that because
the biomass contained in the FIT cartridges is consider-
ably lower than that in stool, the analysis was more sen-
sitive to contaminants in our reagents or the FIT
cartridges themselves [21]. This seems to be the case for
genus Pantoea, since a sequence classified as Pantoea
was detected in several uninoculated FIT cartridges used
as negative controls. It is also possible that storage con-
ditions could have played a role in biasing the relative
abundances of certain genera. The feces in the FIT
cartridges spent more time exposed to ambient tempera-
tures while being analyzed for hemoglobin concentra-
tion. Therefore, it is possible that certain bacterial
populations, especially aerobes, were able to grow. Alter-
natively, there could have been a difference in DNA ex-
traction efficiency between the stool samples and FIT
cartridge buffer. Actinobacteria, which were overrepre-
sented in stool samples, require mechanical lysis for
DNA extraction [22]. It is possible that the particulates
in stool allowed for more efficient mechanical lysis of
Actinobacteria cells compared to the FIT cartridge buf-
fer. Regardless, these biases had no effect on the ability
to detect CRC from FIT cartridge-derived DNA, as the
random forest feature selection process did not select
these populations.
Colonoscopy, rather than stool screening, remains the
more effective CRC screening approach. However, nonin-
vasive stool tests, including those based on microbiota,
might have future utility in directing high risk subjects to-
ward a colonoscopy, increasing the overall performance of
CRC screening and reducing morbidity and mortality. The
ability to assay hemoglobin quantification and microbiota-
based biomarkers with single sampling kit would reduce
cost and improve efficiency. It would also facilitate com-
bining results from the two methods into single model for
predicting the presence of lesions, which has been shown
to improve sensitivity over either method alone. Incorpor-
ating other host-associated stool biomarkers and clinical
data could further improve the accuracy of such a model.
Conclusions
The findings from this study demonstrate the potential
for using DNA from FIT cartridges for microbiota-based
screening. This could reduce the need to collect and
process separate stool samples, decreasing the cost of
screening. It is also possible to use FIT cartridges rather
than separate stool samples for future studies on the role
of the gut microbiota and cancer. Samples collected
from patients who undergo annual FIT screening could
be used to monitor temporal changes in a patient’s
microbiota, making it possible to detect shifts toward a
disease-associated microbiota. Since FIT cartridges are
currently used for CRC screening, our findings may fa-
cilitate large-scale validations of microbiota-based
screening methods.
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